{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:03:57Z","timestamp":1787965437636,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001863","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","award":["Next Generation AI Technology Field: Strategic Advancement of Multi-Purpose Ultra-Human"],"award-info":[{"award-number":["Next Generation AI Technology Field: Strategic Advancement of Multi-Purpose Ultra-Human"]}],"id":[{"id":"10.13039\/501100001863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001863","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","award":["AI Technologies (SamuRAI)"],"award-info":[{"award-number":["AI Technologies (SamuRAI)"]}],"id":[{"id":"10.13039\/501100001863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003051","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","award":["Next Generation AI Technology Field: Strategic Advancement of Multi-Purpose Ultra-Human"],"award-info":[{"award-number":["Next Generation AI Technology Field: Strategic Advancement of Multi-Purpose Ultra-Human"]}],"id":[{"id":"10.13039\/501100003051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003051","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","award":["AI Technologies (SamuRAI)"],"award-info":[{"award-number":["AI Technologies (SamuRAI)"]}],"id":[{"id":"10.13039\/501100003051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rapidly expanding clones (RECs) are one of the single-cell-derived mesenchymal stem cell clones sorted from human bone marrow mononuclear cells (BMMCs), which possess advantageous features. The RECs exhibit long-lasting proliferation potency that allows more than 10 repeated serial passages in vitro, considerably benefiting the manufacturing process of allogenic MSC-based therapeutic products. Although RECs aid the preparation of large-variation clone libraries for a greedy selection of better-quality clones, such a selection is only possible by establishing multiple-candidate cell banks for quality comparisons. Thus, there is a high demand for a novel method that can predict \u201clow-risk and high-potency clones\u201d early and in a feasible manner given the excessive cost and effort required to maintain such an establishment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>LNGFR and Thy-1 co-positive cells from BMMCs were single-cell-sorted into 96-well plates, and only fast-growing clones that reached confluency in 2\u00a0weeks were picked up and passaged as RECs. Fifteen RECs were prepared as passage 3 (P3) cryostock as the primary cell bank. From this cryostock, RECs were passaged until their proliferation limitation; their serial-passage limitation numbers were labeled as serial-passage potencies. At the P1 stage, phase-contrast microscopic images were obtained over 6\u201390\u00a0h to identify time-course changes of 24 morphological descriptors describing cell population information. Machine learning models were constructed using the morphological descriptors for predicting serial-passage potencies. The time window and field-of-view-number effects were evaluated to identify the most efficient image data usage condition for realizing high-performance serial-passage potency models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Serial-passage test results indicated variations of 7\u201313-repeated serial-passage potencies within RECs. Such potency values were predicted quantitatively with high performance (RMSE\u2009&lt;\u20091.0) from P1 morphological profiles using a LASSO model. The earliest and minimum effort predictions require 6\u201330\u00a0h with 40 FOVs and 6\u201390\u00a0h with 15 FOVs, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We successfully developed a noninvasive morphology-based machine learning model to enhance the efficiency of establishing cell banks with single-cell-derived RECs for quantitatively predicting the future serial-passage potencies of clones. Conventional methods that can make noninvasive and quantitative predictions without wasting precious cells in the early stage are lacking; the proposed method will provide a more efficient and robust cell bank establishment process for allogenic therapeutic product manufacturing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41232-022-00214-w","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T02:03:38Z","timestamp":1664676218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Morphology-based noninvasive early prediction of serial-passage potency enhances the selection of clone-derived high-potency cell bank from mesenchymal stem cells"],"prefix":"10.1186","volume":"42","author":[{"given":"Takashi","family":"Suyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-9407","authenticated-orcid":false,"given":"Ryuji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,2]]},"reference":[{"key":"214_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3389\/fimmu.2017.01770","volume":"8","author":"F Marofi","year":"2017","unstructured":"Marofi F, Vahedi G, Biglari A, Esmaeilzadeh A, Athari SS. Mesenchymal stromal\/stem cells: a new era in the cell-based targeted gene therapy of cancer. Front Immunol. 2017;8:1770. https:\/\/doi.org\/10.3389\/fimmu.2017.01770.","journal-title":"Front Immunol"},{"issue":"1","key":"214_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcyt.2016.09.007","volume":"19","author":"LS Sherman","year":"2017","unstructured":"Sherman LS, Shaker M, Mariotti V, Rameshwar P. Mesenchymal stromal\/stem cells in drug therapy: new perspective. Cytotherapy. 2017;19(1):19\u201327. https:\/\/doi.org\/10.1016\/j.jcyt.2016.09.007.","journal-title":"Cytotherapy"},{"issue":"5","key":"214_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"T Squillaro","year":"2016","unstructured":"Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829\u201348. https:\/\/doi.org\/10.3727\/096368915X689622.","journal-title":"Cell Transplant"},{"issue":"24","key":"214_CR4","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.1073\/pnas.1100816108","volume":"108","author":"S Wakao","year":"2011","unstructured":"Wakao S, Kitada M, Kuroda Y, Shigemoto T, Matsuse D, Akashi H, Tanimura Y, Tsuchiyama K, Kikuchi T, Goda M, Nakahata T, Fujiyoshi Y, Dezawa M. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci USA. 2011;108(24):9875\u201380. https:\/\/doi.org\/10.1073\/pnas.1100816108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"214_CR5","first-page":"126","volume":"88","author":"W Vogel","year":"2003","unstructured":"Vogel W, Gr\u00fcnebach F, Messam CA, Kanz L, Brugger W, B\u00fchring HJ. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica. 2003;88(2):126\u201333.","journal-title":"Haematologica"},{"key":"214_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.lfs.2015.09.019","volume":"141","author":"D Trivanovi\u0107","year":"2015","unstructured":"Trivanovi\u0107 D, Jaukovi\u0107 A, Popovi\u0107 B, Krsti\u0107 J, Mojsilovi\u0107 S, Oki\u0107-Djordjevi\u0107 I, Kukolj T, Obradovi\u0107 H, Santibanez JF, Bugarski D. Mesenchymal stem cells of different origin: comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression. Life Sci. 2015;141:61\u201373. https:\/\/doi.org\/10.1016\/j.lfs.2015.09.019.","journal-title":"Life Sci"},{"issue":"6","key":"214_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.stemcr.2016.05.011","volume":"6","author":"B Sacchetti","year":"2016","unstructured":"Sacchetti B, Funari A, Remoli C, et al. No identical \u201cmesenchymal stem cells\u201d at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Reports. 2016;6(6):897\u2013913. https:\/\/doi.org\/10.1016\/j.stemcr.2016.05.011.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"214_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13287-017-0705-0","volume":"8","author":"A Bakopoulou","year":"2017","unstructured":"Bakopoulou A, Apatzidou D, Aggelidou E, Gousopoulou E, Leyhausen G, Volk J, Kritis A, Koidis P, Geurtsen W. Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects \u201cstemness\u201d properties. Stem Cell Res Ther. 2017;8(1):247. https:\/\/doi.org\/10.1186\/s13287-017-0705-0.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"214_CR9","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1073\/pnas.97.7.3213","volume":"97","author":"DC Colter","year":"2000","unstructured":"Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA. 2000;97(7):3213\u20138. https:\/\/doi.org\/10.1073\/pnas.97.7.3213.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"214_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.stemcr.2013.06.001","volume":"1","author":"Y Mabuchi","year":"2013","unstructured":"Mabuchi Y, Morikawa S, Harada S, Niibe K, Suzuki S, Renault-Mihara F, Houlihan DD, Akazawa C, Okano H, Matsuzaki Y. LNGFR+THY-1+VCAM-1hi+ cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem Cell Reports. 2013;1(2):152\u201365. https:\/\/doi.org\/10.1016\/j.stemcr.2013.06.001.","journal-title":"Stem Cell Reports"},{"issue":"8","key":"214_CR11","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.20.00606","volume":"103","author":"D Ukeba","year":"2021","unstructured":"Ukeba D, Yamada K, Tsujimoto T, Ura K, Nonoyama T, Iwasaki N, Sudo H. Bone marrow aspirate concentrate combined with in situ forming bioresorbable gel enhances intervertebral disc regeneration in rabbits. J Bone Joint Surg. 2021;103(8): e31. https:\/\/doi.org\/10.2106\/JBJS.20.00606.","journal-title":"J Bone Joint Surg"},{"key":"214_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coph.2018.03.009","volume":"40","author":"C De Bari","year":"2018","unstructured":"De Bari C, Roelofs AJ. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. Curr Opin Pharmacol. 2018;40:74\u201380. https:\/\/doi.org\/10.1016\/j.coph.2018.03.009.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"214_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/sctm.19-0202","volume":"9","author":"M Kabat","year":"2020","unstructured":"Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004\u20132018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9(1):17\u201327. https:\/\/doi.org\/10.1002\/sctm.19-0202.","journal-title":"Stem Cells Transl Med"},{"issue":"11","key":"214_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1089\/scd.2013.0591","volume":"23","author":"S Viswanathan","year":"2014","unstructured":"Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, Mason C, Rao MS. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells and Development. 2014;23(11):1157\u201367. https:\/\/doi.org\/10.1089\/scd.2013.0591.","journal-title":"Stem Cells and Development"},{"key":"214_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.addr.2017.06.005","volume":"114","author":"NJ Dwarshuis","year":"2017","unstructured":"Dwarshuis NJ, Parratt K, Santiago-Miranda A, Roy K. Cells as advanced therapeutics: state-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. Adv Drug Deliv Rev. 2017;114:222\u201339. https:\/\/doi.org\/10.1016\/j.addr.2017.06.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"214_CR16","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00253-018-8912-x","volume":"102","author":"V Jossen","year":"2018","unstructured":"Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbiol Biotechnol. 2018;102:3981\u201394. https:\/\/doi.org\/10.1007\/s00253-018-8912-x.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"11","key":"214_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1089\/ten.tec.2011.0736","volume":"18","author":"J Lo Surdo","year":"2012","unstructured":"Lo Surdo J, Bauer SR. Quantitative approaches to detect donor and passage differences in adipogenic potential and clonogenicity in human bone marrow-derived mesenchymal stem cells. Tissue Engineering - Part C: Methods. 2012;18(11):877\u201389. https:\/\/doi.org\/10.1089\/ten.tec.2011.0736.","journal-title":"Tissue Engineering - Part C: Methods"},{"issue":"1","key":"214_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13287-018-0914-1","volume":"9","author":"S Mohamed-Ahmed","year":"2018","unstructured":"Mohamed-Ahmed S, Fristad I, Lie SA, Suliman S, Mustafa K, Vindenes H, Idris SB. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. Stem Cell Res Ther. 2018;9(1):168. https:\/\/doi.org\/10.1186\/s13287-018-0914-1.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"214_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3109\/17453670903278241","volume":"80","author":"EM Fennema","year":"2009","unstructured":"Fennema EM, Renard AJS, Leusink A, Van Blitterswijk CA, De Boer J. The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells. Acta Orthop. 2009;80(5):618\u201321. https:\/\/doi.org\/10.3109\/17453670903278241.","journal-title":"Acta Orthop"},{"issue":"7","key":"214_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.4252\/wjsc.v7.i7.1010","volume":"7","author":"P-Y Collart-Dutilleul","year":"2015","unstructured":"Collart-Dutilleul P-Y, Chaubron F, De Vos J, Cuisinier FJ. Allogenic banking of dental pulp stem cells for innovative therapeutics. World Journal of Stem Cells. 2015;7(7):1010\u201321. https:\/\/doi.org\/10.4252\/wjsc.v7.i7.1010.","journal-title":"World Journal of Stem Cells"},{"key":"214_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15419\/psc.v4i3-4.397","volume":"4","author":"S Nievaleve","year":"2017","unstructured":"Nievaleve S. Concise review: umbilical cord derived mesenchymal stem cell bank. Progress in Stem Cell. 2017;4:3\u20134. https:\/\/doi.org\/10.15419\/psc.v4i3-4.397.","journal-title":"Progress in Stem Cell"},{"key":"214_CR22","doi-asserted-by":"publisher","first-page":"8835986","DOI":"10.1155\/2020\/8835986","volume":"2020","author":"FA Alzahrani","year":"2020","unstructured":"Alzahrani FA, Saadeldin IM, Ahmad A, Kumar D, Azhar EI, Siddiqui AJ, Kurdi B, Sajini A, Alrefaei AF, Jahan S. The potential use of mesenchymal stem cells and their derived exosomes as immunomodulatory agents for COVID-19 patients. Stem Cells International. 2020;2020:8835986. https:\/\/doi.org\/10.1155\/2020\/8835986.","journal-title":"Stem Cells International"},{"issue":"1","key":"214_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.leu.2402763","volume":"17","author":"WJC Rombouts","year":"2003","unstructured":"Rombouts WJC, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17(1):160\u201370. https:\/\/doi.org\/10.1038\/sj.leu.2402763.","journal-title":"Leukemia"},{"issue":"2","key":"214_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10561-012-9311-7","volume":"14","author":"M Dhanasekaran","year":"2013","unstructured":"Dhanasekaran M, Indumathi S, Poojitha R, Kanmani A, Rajkumar JS, Sudarsanam D. Plasticity and banking potential of cultured adipose tissue derived mesenchymal stem cells. Cell Tissue Banking. 2013;14(2):303\u201315. https:\/\/doi.org\/10.1007\/s10561-012-9311-7.","journal-title":"Cell Tissue Banking"},{"issue":"1","key":"214_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13643-020-01437-z","volume":"9","author":"C Dave","year":"2020","unstructured":"Dave C, McRae A, Doxtator E, Mei SHJ, Sullivan K, Wolfe D, Champagne J, McIntyre L. Comparison of freshly cultured versus freshly thawed (cryopreserved) mesenchymal stem cells in preclinical in vivo models of inflammation: a protocol for a preclinical systematic review and meta-analysis. Syst Rev. 2020;9(1):188. https:\/\/doi.org\/10.1186\/s13643-020-01437-z.","journal-title":"Syst Rev"},{"issue":"1","key":"214_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13287-019-1334-6","volume":"10","author":"D Hladik","year":"2019","unstructured":"Hladik D, H\u00f6fig I, Oestreicher U, Beckers J, Matjanovski M, Bao X, Scherthan H, Atkinson MJ, Rosemann M. Long-term culture of mesenchymal stem cells impairs ATM-dependent recognition of DNA breaks and increases genetic instability. Stem Cell Res Ther. 2019;10(1):218. https:\/\/doi.org\/10.1186\/s13287-019-1334-6.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"214_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/ijms140917986","volume":"14","author":"HJ Jin","year":"2013","unstructured":"Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, Kim SW, Yang YS, Oh W, Chang JW. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013;14(9):218. https:\/\/doi.org\/10.3390\/ijms140917986.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"214_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-018-0876-3","volume":"9","author":"YHK Yang","year":"2018","unstructured":"Yang YHK, Ogando CR, Wang See C, Chang TY, Barabino GA. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther. 2018;9(1):131. https:\/\/doi.org\/10.1186\/s13287-018-0876-3.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"214_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002213","volume":"3","author":"W Wagner","year":"2008","unstructured":"Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE. 2008;3(5): e2213. https:\/\/doi.org\/10.1371\/journal.pone.0002213.","journal-title":"PLoS ONE"},{"issue":"7","key":"214_CR30","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/ijms17071164","volume":"17","author":"V Turinetto","year":"2016","unstructured":"Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int J Mol Sci. 2016;17(7):1164. https:\/\/doi.org\/10.3390\/ijms17071164.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"214_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cpr.12002","volume":"46","author":"R Binato","year":"2013","unstructured":"Binato R, de Souza FT, Lazzarotto-Silva C, Du Rocher B, Mencalha A, Pizzatti L, Bouzas LF, Abdelhay E. Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif. 2013;46(1):10\u201322. https:\/\/doi.org\/10.1111\/cpr.12002.","journal-title":"Cell Prolif"},{"issue":"6","key":"214_CR32","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333. https:\/\/doi.org\/10.1016\/j.stem.2018.05.004.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"214_CR33","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","volume":"6","author":"RM Samsonraj","year":"2017","unstructured":"Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6(12):2173\u201385. https:\/\/doi.org\/10.1002\/sctm.17-0129.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"214_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.reth.2018.06.001","volume":"9","author":"Y Imai","year":"2018","unstructured":"Imai Y, Yoshida K, Matsumoto M, Okada M, Kanie K, Shimizu K, Honda H, Kato R. In-process evaluation of culture errors using morphology-based image analysis. Regenerative Therapy. 2018;9(9):15\u201323. https:\/\/doi.org\/10.1016\/j.reth.2018.06.001.","journal-title":"Regenerative Therapy"},{"issue":"2","key":"214_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055082","volume":"8","author":"F Matsuoka","year":"2013","unstructured":"Matsuoka F, Takeuchi I, Agata H, Kagami H, Shiono H, Kiyota Y, Honda H, Kato R. Morphology-based prediction of osteogenic differentiation potential of human mesenchymal stem cells. PLoS ONE. 2013;8(2): e55082. https:\/\/doi.org\/10.1371\/journal.pone.0055082.","journal-title":"PLoS ONE"},{"issue":"4","key":"214_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093952","volume":"9","author":"H Sasaki","year":"2014","unstructured":"Sasaki H, Takeuchi I, Okada M, Sawada R, Kanie K, Kiyota Y, Honda H, Kato R. Label-free morphology-based prediction of multiple differentiation potentials of human mesenchymal stem cells for early evaluation of intact cells. PLoS ONE. 2014;9(4): e93952. https:\/\/doi.org\/10.1371\/journal.pone.0093952.","journal-title":"PLoS ONE"},{"issue":"2","key":"214_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jbiosc.2020.09.022","volume":"131","author":"Y Takemoto","year":"2020","unstructured":"Takemoto Y, Imai Y, Kanie K, Kato R. Predicting quality decay in continuously passaged mesenchymal stem cells by detecting morphological anomalies. J Biosci Bioeng. 2020;131(2):198\u2013206. https:\/\/doi.org\/10.1016\/j.jbiosc.2020.09.022.","journal-title":"J Biosci Bioeng"},{"issue":"3","key":"214_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10047-006-0338-z","volume":"9","author":"R Sawada","year":"2006","unstructured":"Sawada R, Ito T, Tsuchiya T. Changes in expression of genes related to cell proliferation in human mesenchymal stem cells during in vitro culture in comparison with cancer cells. J Artif Organs. 2006;9(3):179\u201384. https:\/\/doi.org\/10.1007\/s10047-006-0338-z.","journal-title":"J Artif Organs"},{"issue":"7","key":"214_CR39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1242\/jcs.113.7.1161","volume":"113","author":"A Muraglia","year":"2000","unstructured":"Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci. 2000;113(7):1161\u20136. https:\/\/doi.org\/10.1242\/jcs.113.7.1161.","journal-title":"J Cell Sci"},{"issue":"7151","key":"214_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313\u20137. https:\/\/doi.org\/10.1038\/nature05934.","journal-title":"Nature"},{"issue":"9","key":"214_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/stem.471","volume":"28","author":"I Gutierrez-Aranda","year":"2010","unstructured":"Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, M\u00e1cia A, Sanchez L, Ligero G, Garcia-Parez JL, Menendez P. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010;28(9):1568\u201370. https:\/\/doi.org\/10.1002\/stem.471.","journal-title":"Stem Cells"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-022-00214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-022-00214-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-022-00214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T02:04:40Z","timestamp":1664676280000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-022-00214-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1186\/s41232-022-00214-w","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,2]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS, HM, and YK are employees of PuREC, whose main business product is REC cells. YM is the CTO of PuREC, whose main business product is REC cells, and owns a stock share.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}